TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05928598

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survey questionnaires
Description: Participants will be enrolled before a scheduled clinic appointment. Following the clinic visit, the research staff will ask the patient to complete questionnaires electronically (or by phone if patient prefers) within three days after the baseline clinic visit and then at three months following this visit. Additionally, some data will be obtained from the participant's medical record.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Survey questionnaires
Description: Participants will be enrolled before a scheduled clinic appointment. Following the clinic visit, the research staff will ask the patient to complete questionnaires electronically (or by phone if patient prefers) within three days after the baseline clinic visit and then at three months following this visit. Additionally, some data will be obtained from the participant's medical record.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Epilepsy Visit Planner
Description: Participants will be identified before a scheduled clinic appointment. Prior to the clinic visit (at the site) the participants will meet with a research staff to obtain written informed consent and then present the Epilepsy Visit Planner to the patient. Participants will be encouraged to use the Planner and share the Planner's output with the provider during the clinic visit. In some cases, there could be an option for the participants to consent prior to the visit and have a virtual presentation of the Planner.~Following the clinic visit, the research staff will ask the participants to complete questionnaires electronically (or by phone if patient prefers) within three days after the baseline clinic visit and then at three months following this visit. Additionally, some data will be obtained from the participant's medical record.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires for Providers
Description: Providers will be asked to complete a survey after the clinic visit for the intervention group.
Study: NCT05371184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Glutamine, Oral Powder for Reconstitution
Description: Glutamine is an essential amino acid. It will be provided in a powder form. It will be dissolved in at least 8 ounces of hot or cold liquid. It can also be mixed with a soft food such as pudding, applesauce, or yogurt. Then it will be Stirred and then eaten or drunken The Glutamine will be as an add on to the Standard of care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Hydroxyurea 15-25 mg per kg per day and/ or blood transfusion therapy
Study: NCT02856932

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional high viscosity glass ionomer
Description: Dental restorative material

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glass ionomer with glass hybrid technology
Description: Dental restorative material
Study: NCT06120426

Intervention type: PROCEDURE
Intervention: total en bloc spondylectomy
Description: Total enbloc resection (TES) is one of the most challenging surgeries in spinal surgery and a classic surgical method. It not only relieve spinal cord compression and delays tumor recurrence, but also prolongs patient survival, significantly reduces hand surgery trauma, and improves surgical safety. However, for cases with extensive tumor invasion, methods such as separation surgery should be used to relieve spinal cord nerve compression, rebuild spinal stability, and provide conditions for postoperative radiotherapy.
Study: NCT05679739

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized blood pressure strategy
Description: An individualized blood pressure strategy targeting cerebral blood flow, serially guided by near-infrared spectroscopy and transcranial Doppler ultrasound. Assessments are performed on admission, and at 12, 24 and 48 hours post-ROSC.
Study: NCT04861727

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRPA procedure
Description: The patient will receive the device for BP measurement at home for a week and two daily measurements will be taken, one in the morning (between 6 and 10 am) and one in the afternoon / evening (between 6 pm and 10 pm), for seven days. At the end of the procedure, it is expected to record 14 measurements (representing a total of 42 in seven days), but it is considered feasible when at least 10 results are recorded, respecting the number of two measurements per day, in the periods oriented. Participants who do not reach the satisfactory number of measures or do not check between the times mentioned above, will be invited to repeat the procedure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmaceutical intervention
Description: The suggestion procedure, for this research, is defined as the pharmaceutical act of forwarding a letter of suggestion to the prescriber, previously agreed with the patient, based on clinical evaluation, review of pharmacotherapy, adherence to treatment and result of the MRPA procedure.
Study: NCT06577779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Hydrochloride Extended Release Capsule
Description: Subjects will start at dose of 40mg (DR/ER-MPH) day with titrations of 20mg leading to a maximum dose of 100mg (DR/ER-MPH).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate Hydrochloride Extended Release Capsule
Description: Subjects will start at dose of 40mg (DR/ER-MPH) day with titrations of 20mg leading to a maximum dose of 100mg (DR/ER-MPH).
Study: NCT04648761

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OPTIMAL algorithm
Description: The OPTIMAL algorithm titrates anti IL 5 treatment by addjusting the intervals between injections by FEV1, blood eosinophils and exacerbations.
Study: NCT05218967

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Headset
Description: A head-worn apparatus that completely covers the eyes for an immersive 3D experience. The VR headset will be worn during the procedure.
Study: NCT05049018

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physical Therapy Program
Description: This intervention included:~* Strengthening and facilitation exercises for the affected upper extremity muscles.~* Stretching and mobilization exercises for the affected upper extremity muscles and joints.~* Postural reactions exercises.~* Facilitation of arm-reaching and arm-hand skills for the affected upper extremity.~* Facilitation of manipulative tasks (grasp and release activities) for the affected upper extremity.~* Training of daily living activities for the upper extremities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Physical Therapy Program
Description: This intervention included:~* Strengthening and facilitation exercises for the affected upper extremity muscles.~* Stretching and mobilization exercises for the affected upper extremity muscles and joints.~* Postural reactions exercises.~* Facilitation of arm-reaching and arm-hand skills for the affected upper extremity.~* Facilitation of manipulative tasks (grasp and release activities) for the affected upper extremity.~* Training of daily living activities for the upper extremities.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ArmeoSpring Virtual Reality Device (Upper Extremity Training Device with Virtual Reality Technology)
Description: ArmeoSpring virtual Reality Equipment is a functional upper extremity rehabilitation device that provides specific therapy with augmented feedback. The ArmeoSpring instrument facilitates intensive task-oriented upper extremity therapy after stroke, traumatic brain injury, or other neurological diseases and injuries. It combines adjustable arm support, with augmented feedback and a large 3 D workspace that allows functional therapy exercises in a virtual reality environment.
Study: NCT05177822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Anakinra 100 mg/0.67 mL daily subcutaneous injection for up to 14 days, including up to 9 days outpatient treatment;

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% NaCl/0.67 mL daily subcutaneous injection for up to 14 days, including up to 9 days outpatient treatment.
Study: NCT03811886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalizumab
Description: Natalizumab is an FDA approved monotherapy for treatment of relapsing forms of MS. It is also indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active CD who have had an inadequate response to, or intolerance of, conventional therapies and TNF-α inhibitors.~Traditional 3+3 escalation of Natalizumab at a weight-based dosing 2mg/kg not to exceed 300mg. If no subjects experience a dose limiting toxicity (DLT), 3 more subjects are enrolled at the next dose of 3mg/kg, not to exceed 300mg. If no subjects experience a DLT, 3 more subjects will be enrolled at the next and final dose of 4mg/kg, not to exceed 300mg.~Phase II will continue if the subject has Complete Response (CR), Partial Response (PR) or Stable Disease (SD) of pOS, defined by RECIST 1.1 criteria after every 3 cycles after the first 6 cycles but not beyond 24 cycles. If subject has progressive disease after cycle 6, they will be removed from the study.
Study: NCT06439563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JP-1366 10 mg
Description: JP-1366 10 mg, tablet, orally once a day for up to 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanston Capsule 15 mg
Description: Lanston Capsule 15 mg orally once a day for up to 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JP-1366 10 mg placebo
Description: JP-1366 10 mg placebo, tablet, orally once a day for up to 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanston Capsule 15 mg placebo
Description: Lanston Capsule 15 mg placebo, orally once a day for up to 24 weeks
Study: NCT06354712

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetyl-Cysteine with Institutional standard care
Description: A potent antioxidant and anti-inflammatory drug (A precursor of the endogenous antioxidant glutathione)

Intervention type: DRUG
Group type: OTHER
Intervention: Institutional standard care
Description: Benzydamine Mouthwash
Study: NCT06121349

Intervention type: DRUG
Intervention: ocrelizumab
Description: infusion therapy administered every six months

Intervention type: DRUG
Intervention: ofatumumab
Description: self-injectable every month
Study: NCT04645160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib
Description: Oral tivozanib taken daily for Days 1-21 continuously (of each 28-day cycle) followed with 7 days off medication (except for patients in DL-1, with dosing every other day of the 28-day cycle). Phase I: The starting dose (DL1) is 0.89 mg taken once a day continuously for Days 1-21 with 1 week off medication (except for those patients assigned to DL-1, where tivozanib should be taken every other day, around 48 hours apart in 28-day cycle). Patients may escalate to 1.34 mg taken once a day (DL2) continuously for Days 1-21 with 1 week off medication for their second cycle if there are no dose-limiting toxicities. Phase II: Tivozanib dose level will be at the recommended Phase II dose (RP2D) established in Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib
Description: Oral tivozanib taken daily for Days 1-21 continuously (of each 28-day cycle) followed with 7 days off medication (except for patients in DL-1, with dosing every other day of the 28-day cycle). Phase I: The starting dose (DL1) is 0.89 mg taken once a day continuously for Days 1-21 with 1 week off medication (except for those patients assigned to DL-1, where tivozanib should be taken every other day, around 48 hours apart in 28-day cycle). Patients may escalate to 1.34 mg taken once a day (DL2) continuously for Days 1-21 with 1 week off medication for their second cycle if there are no dose-limiting toxicities. Phase II: Tivozanib dose level will be at the recommended Phase II dose (RP2D) established in Phase I.
Study: NCT05635708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tislelizumab
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A445
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A445
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBL-007
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBL-007
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Investigator's choice; administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Investigator's choice; administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Investigator's choice; administered by intravenous infusion
Study: NCT05664009

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Redsenol-1 Plus
Description: Two capsules of Redsenol-1 Plus will be taken three times per day for 12 weeks (84 days).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two capsules of Placebo will be taken three times per day for 12 weeks (84 days).
Study: NCT04822025

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVC-COV1901 (High-Dose)
Description: Approximately 300 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVC-COV1901(Mid-Dose)
Description: Approximately 100 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region
Study: NCT04724668

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Melatonin (3hrs before DLMO)
Description: Melatonin 3mg (3hrs before DLMO)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo (3hrs before DLMO)
Description: Placebo capsule (3hrs before DLMO)

Intervention type: DEVICE
Group type: OTHER
Intervention: Morning light version 1
Description: Morning light version

Intervention type: DEVICE
Group type: OTHER
Intervention: Morning light version 2
Description: Morning light version
Study: NCT05858047

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally, once daily (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHX1901
Description: Administered orally, once daily (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHX1901
Description: Administered orally, once daily (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHX1901
Description: Administered orally, once daily (QD)
Study: NCT05041478

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold Snare Endoscopic mucosal resection with adjuvant snare tip soft coagulation
Description: Use of injected chromogelofusine solution to raise a lesion prior to polypectomy. Lesion then removed with a stiff thin-wired snare. Following this defect margins are treated with electrocautery to create a rim of ablated tissue.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cold Snare Endoscopic Mucosal Resection
Description: Use of injected chromogelofusine solution to raise a lesion prior to polypectomy. Lesion then removed with a stiff thin-wired snare.
Study: NCT04715711

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Forearm coolng
Description: forearm immersion will be performed for active cooling assessment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wet-towel cooling
Description: Wet towels will be wrapped around the participant's arms for active cooling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mist-fan
Description: a mist-fan will be placed in front of the participant for active cooling

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: passive cooling
Description: participants will sit in a chair and passively cool (no active intervention)
Study: NCT05559164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipitor 40mg Tablet
Description: LIPITOR® (atorvastatin calcium) tablets will be administered orally as a single dose of 40 mg once daily, with or without food
Study: NCT04864236

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel isolation device to contain aerosol
Description: The novel isolation device is called SLACC (Suction-assisted Local Aerosol Containment Chamber). SLACC has the ability to isolate the atmosphere around the patient's upper airway (nose, mouth, throat) via negative pressure in a manner analogous to isolation rooms used to house patients with communicable diseases spread by aerosol (e.g. tuberculosis).~The SLACC uses an external suction source to maintain a negative pressure micro-atmosphere around a patient's head (the source of infectious aerosols). The components of SLACC include a clear polymer frame, a flexible drape, and integrated sealed arm sleeves to protect the hands and forearms of the health care provider. The structure is flexible during use, transparent, can be rapidly assembled, and easily collapsible for removal and transport. Once deployed with the patient's head inside the chamber, the drape is secured across the open side of the chamber with adhesive and covers the patient's torso.
Study: NCT06440980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orforglipron
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orforglipron
Description: Administered orally
Study: NCT03017716

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gluten free diet
Description: The investigators will evaluate the effect of a gluten free diet (GFD) in IBP patients, randomly assigned to receive standard therapy for IBP or standard therapy for IBP plus GFD, for a period of at least one year.
Study: NCT05099978

Intervention type: GENETIC
Intervention: NGS analysis of ctDNA
Description: Diagnostic Test: plasma circulating tumor DNA
Study: NCT05063162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab
Description: * Pharmaceutical form: Solution for infusion~* Route of administration: subcutaneous infusion~Participants will receive pre-specified doses of rozanolixizumab.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Pharmaceutical form: Solution for infusion~* Route of administration: subcutaneous infusion~Participants will receive placebo.
Study: NCT04908800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRP-A218
Description: KRP-A218 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRP-A218
Description: KRP-A218 tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole
Description: 10 mg/mL oral solution
Study: NCT06646146

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat grafting combine with hair transplantation
Description: Patients enrolled in this experiment will be divided into two groups.The experimental group will have autologous fat tissue harvested during surgery for fat grafting in the patient's alopecia area, and a subsequent hair transplantation will be performed after three months when the transplanted fat has stabilized and survived.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hair transplantation
Description: Patients enrolled in this experiment will be divided into two groups. The control group will undergo a simple hair transplantation surgery.
Study: NCT03978702

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: 20 mL will be collected at each time point (day-1,day 0, day 1, day 3, day 7, 1 year after pancreatectomy)
Study: NCT05785520

Intervention type: DEVICE
Group type: OTHER
Intervention: ST500 SINGLE-DOSE GEL
Description: ST500 SINGLE-DOSE GEL is a hydrogel to be applied to intact skin, useful to limit the physiological degeneration of the joints and tissues, improving their functionality. The presence of a peptide mixture and sodium hyaluronate facilitates the movement of joints and tendons for greater mobility and flexibility.
Study: NCT05245773

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Automated SMS program to support post-discharge transitions of care
Description: The intervention will consist of automated text messages on a tapering schedule over the course of 30 days post-discharge, with responses escalated back to the practice care management team. After initial enrollment messages, patients will receive check-in messages on a tapering schedule over the course of 30 days. For the first week they will receive 3 total messages; the second week they will receive a total of 2 messages. For the last 2 weeks they will receive weekly messages. If a patient need is identified, the request will be escalated to the practice (triaged by the care management RN) for a follow up phone call. Patients will be able to reach out at any time by sending a message to the same number, and they will be entered into the same pathway. For any escalated need, patients will receive a follow up phone call from the practice staff.
Study: NCT06378983

Intervention type: DRUG
Group type: OTHER
Intervention: Oral isotretinoin
Description: Oral isotretinoin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral isotretinoin combined with microneedle radiofrequency therapy
Description: Oral isotretinoin combined with microneedle radiofrequency therapy